BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/23/2024 9:31:45 AM | Browse: 68 | Download: 163
 |
Received |
|
2023-10-20 02:03 |
|
Peer-Review Started |
|
2023-10-20 02:04 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-11-16 07:21 |
|
Revised |
|
2023-11-21 03:13 |
|
Second Decision |
|
2023-12-05 23:45 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-12-12 08:02 |
|
Articles in Press |
|
2023-12-12 08:02 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-12-05 03:14 |
|
Typeset the Manuscript |
|
2024-01-18 07:21 |
|
Publish the Manuscript Online |
|
2024-01-23 09:31 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Sorafenib plus transarterial chemoembolization vs sorafenib alone for patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hong-Jie Yang, Bin Ye, Jia-Xu Liao, Lei Lei and Kai Chen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Sichuan Science and Technology Project |
2021YJ0138 |
| Research Subject of Sichuan Provincial Health Commission |
19PJ007 |
| Chengdu Science and Technology Project |
2021-YF05-01788-SN |
|
| Corresponding Author |
Kai Chen, N/A, Pharmacist, Department of Pharmacy, The Affiliated Taizhou People's Hospital of Nanjing Medical University, No. 366 Taihu Road, Taizhou 225300, Jiangsu Province, China. kaichen@njmu.edu.cn |
| Key Words |
Hepatocellular carcinoma; Sorafenib; Transarterial chemoembolization; Systematic review; Meta-analysis |
| Core Tip |
No consensus is available in the literature about whether addition of transarterial chemoembolization (TACE) could improve survival in patients receiving sorafenib for advanced hepatocellular carcinoma. This is the first systematic review and meta-analysis comparing sorafenib/TACE combination therapy and sorafenib monotherapy for advanced hepatocellular carcinoma. We investigated these two treatments in terms of overall survival, progression free survival, time to progression, disease control rate, and adverse events. |
| Publish Date |
2024-01-23 09:31 |
| Citation |
Yang HJ, Ye B, Liao JX, Lei L, Chen K. Sorafenib plus transarterial chemoembolization vs sorafenib alone for patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis. World J Hepatol 2024; 16(1): 91-102 |
| URL |
https://www.wjgnet.com/1948-5182/full/v16/i1/91.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v16.i1.91 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
